

July 13, 2015

US NRC Licensing Assistance Team 2100 Renaissance Boulevard Suite 100 King of Prussia, PA 19406-2713 Br. 1

西路18815至9時

Re: Request Addition of Authorized User Adam Kaye, MD on St. Vincent's Medical Center Radioactive Materials License No. 06-00843-03/0 370/245

Dear License Reviewer,

Please consider this request to add Dr. Adam Kaye as an Authorized User on Saint Vincent's materials license for the following:

- 35.100 Uptake, dilution, and excretion studies
- 35.200 Imaging and localization studies
- 35.300 Use of unsealed byproduct material for which a written directive is required:
 - o oral administration of sodium iodide I-131 in quantities less than or equal to 1.22 GBq (33 mCi)
 - o oral administration of sodium iodide I-131 in quantities greater than 1.22 GBq (33 mCi)
 - o Parenteral administration of any beta emitter, or photon emitting radionuclide with a photon energy less than 150 keV

Enclosed is a copy of a notification letter from the Radiation Safety Officer of the University of Pennsylvania, informing Dr. Kaye of approve authorized use as stated above on their broad scope materials license, #PA-0131.

If you have any questions or require additional information, please don't hesitate to contact our Radiation Safety Officer, Mr. Sean Mathews.

Sincerely,

Dale Danowski, MBA, BSN, RN

Senior Vice President, Chief Operating Officer / Chief Nursing Officer

Saint Vincent's Medical Center

Enclosures:

AU letter from University of Pennsylvania

University of Connecticut

588349
NMSSIRGNI MATERIALS-002

SCENSION

UNIVERSITY of PENNSYL VANIA

Environmental Health & Radiation Safety 3160 Chestnut Street, Suite 400 Philadelphia, PA 19104-6287

Tel: (215) 898-4453 Fax: (215) 898-0140

June 12, 2015

Dr. Adam Kaye,

This letter is to notify you that on June 5, 2014 you were approved as an Authorized User at the University of Pennsylvania (State of Pennsylvania Broad Scope License # PA-0131) for the following types of radioactive materials uses:

- Uptake, Dilution, and Excretion studies for which a written directive is not required (10 CFR 35.100)
- Imaging and Localization studies for which a written directive is not required (10 CFR 35 200)
- Byproduct material for which a written directive is required (10 CFR 35 300) for the following categories:
 - Oral administration of less than or equal to 1.22 GBq (33 mCi) of sodium iodide I-131
 - Oral administration of greater than 1.22 GBq (33 mCi) of sodium iodide I-131
 - Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV

Sincerely,

Eileen Normoyle

Radiation Safety Officer/Director of Radiation Safety

Environmental Health and Radiation Safety

University of Pennsylvania